This phase I trial is studying the side effects and best dose of temsirolimus when given together with sorafenib in treating patients with unresectable or metastatic solid tumors. Sorafenib and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with temsirolimus may kill more tumor cells.
Name: sorafenib tosylate
Description: Given orallyType: DrugTreatment (sorafenib tosylate, temsirolimus)
Name: temsirolimus
Description: Given IVType: DrugTreatment (sorafenib tosylate, temsirolimus)
Name: laboratory biomarker analysis
Description: Correlative studiesType: OtherTreatment (sorafenib tosylate, temsirolimus)
Single Group Assignment
There is one SNP
To analyze the biologic effects of BAY 43-9006 and CCI-779 on downstream targets of the P13K/Akt/mTOR and Raf signaling pathways. --- P13K ---